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Purpose. Bladder ﬁlling variations have shown dosimetrical consequences on organs of risk during vaginal brachytherapy (VBT).
Fewer reports have been focused on the effect of rectal ﬁlling when treating such patients despite this subject has received great
attention on external irradiation. Our aim was to evaluate the inﬂuence of rectal contrast during VBT on rectal dose deposition.
Materials. Treatment plans of 17 patients treated with fractionated postoperative HDR-VBT were reviewed. A CT-scan was under-
gone on each fraction. No special instructions were given to patients. Rectal contrast was administered in some fractions at
discretion of the treating physician. The rectum was contoured from 1 cm above the tip of cylinders to the caudal well position.
Documented rectal doses were D0.1cc, D1cc, D2cc, D5cc and D10cc. Doses were recorded as percentages from the prescribed
dose. Cross sectional area (CSA) was also calculated.
Results. Seventy-four CT-based plans were reviewed, 3–6 per patient (mean 4.7, median 4). Rectal contrast was administered
on the 16% of fractions. Percentages of fractions with contrast per patient: 0–50%. Mean rectal volume: 47.32 cm3 (No contrast:
45.34 cm3, contrast: 57.73; p=0.155). Mean CSA: 9.15 (No contrast: 8.83, contrast 10.87; p=0.83). Mean D0.1cc: 118.26 (No contrast:
115.1, contrast: 134.81). Mean D1cc: 96.83 (No contrast: 93.93, contrast 112.07). Mean D2cc: 87.56 (No contrast: 84.61, contrast:
103.02). Mean D5cc: 71.45 (No contrast: 68.54, contrast: 86.7). Independent non-parametrical test showed signiﬁcance in all rectal
level doses (all p=0.0005).
Conclusions. These results shown a dismal effect related to the presence of rectal contrast. A signiﬁcant increment of rectal doses
was evident over the full length of the rectal DVH. Our data attract suggest the avoidance of that distend the rectum and, if the
data are conﬁrmed, could warrant emptying the rectum before any vaginal cuff brachytherapy fraction.
http://dx.doi.org/10.1016/j.rpor.2013.03.050
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Introduction. Earlobe keloids are being ﬁbrous proliferation due to traumas such as ear piercing, and often prove to be recurrent,
despite the variety of treatments options, especially following a surgical excision. Recurrent keloids are associated with unsightly
cosmetic consequences, particularly in younger patients. Radiotherapy has been achieved to be a successful treatment in recur-
rent cases. External beam radiotherapy is a difﬁcult treatment to be conformed over the earlobe lesions due to its irregular
anatomy, so brachytherapy should be a good option to be considered.
Purpose. We present the patients that have been treated with surgical excision and perioperative HDR brachytherapy in our
institution.
Materials and methods. 11 patients have been treated with perioperative intersticial brachytherapy. In every patient, after a theo-
retical dosimetry was performed, a total dose of 20Gy in 4 fractions of 5Gy was administrated over the surgical scar, separated
6 hours between every fraction, and the total dose was delivered in the ﬁrst 2 days after the surgical excision.
Results. With a follow up of 5 years, no patient suffered a keloid relapse. Grade 1 dermitis was achieved in all patient around 15
days after the brachytherapy treatment that did not maintain more than one month in any case. Grade 1 ﬁbrosis was achieved
in 6 patients. No cases of cronic pruritus were achieved.
Conclusion. Perioperative intersticial HDR brachytherapy is a well tolerated treatment, that obtains an excellent rate of acute local
control in recurrence earlobe keloids.
http://dx.doi.org/10.1016/j.rpor.2013.03.051
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Introduction. For 3 years 370 patients have been treated with I-125 seed prostate implants, releasing the patients after the surgery
implantation. Systematic measurements of dose rate from them were always taken. Aims To assess these data to compare
conclusions with the ICRP 98 Report, which only recommends two months of duration following special instructions if child or
pregnant are in the vicinity of the patient.
Method. Dose rate at 5 and at 50 cm from patient were measured with a SmartION Ion Chamber calibrated in H’(0.07) from 10keV
shield open and H*(10) from 22keV with it shut. To avoid dependence with source depth two conjugate AP and PA views were
taken. To calculate the doses to sleeping partner, children<2 year and workmates, the domestic and standard activities of patient
